Menu
Search
|

Menu

Close
X

Ultragenyx Pharmaceutical Inc RARE.OQ (NASDAQ Stock Exchange Global Select Market)

62.46 USD
-- (--)
As of Jul 18
Previous Close 62.46
Open --
Volume --
3m Avg Volume 192,088
Today’s High --
Today’s Low --
52 Week High 90.95
52 Week Low 37.98
Shares Outstanding (mil) 42.46
Market Capitalization (mil) 2,305.92
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.84 Mean rating from 19 analysts

KEY STATS

Revenue (mm, USD)
FY19
18
FY18
51
FY17
3
FY16
0
EPS (USD)
FY19
-1.818
FY18
-3.904
FY17
-5.479
FY16
-6.201
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
19,878.61
7.92
Price to Book (MRQ)
vs sector
5.37
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
0.00
14.56
LT Debt to Equity (MRQ)
vs sector
0.00
10.21
Return on Investment (TTM)
vs sector
-62.70
14.49
Return on Equity (TTM)
vs sector
-63.52
15.79

EXECUTIVE LEADERSHIP

Daniel Welch
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Emil Kakkis
President, Chief Executive Officer, Director, Since
Salary: $679,952.00
Bonus: --
Shalini Sharp
Chief Financial Officer, Executive Vice President, Since 2016
Salary: $491,369.00
Bonus: --
Wladimir Hogenhuis
Chief Operating Officer, Since 2018
Salary: $110,923.00
Bonus: $200,000.00
Karah Parschauer
Executive Vice President, General Counsel, Since 2016
Salary: $386,251.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

60 Leveroni Ct
NOVATO   CA   94949-5746

Phone: +1415.4838800

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

SPONSORED STORIES